The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
EBITDA before special items falls 1.3 percent to € 4.41 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
